CClinicalTrials.gg
CompletedNCT02100293Updated Apr 18, 2016

Effects of Magnesium Sulfate on Onset and Duration of Low Dose Rocuronium

An interventional study of magnesium sulfate 30 mg/kg and saline in Observation of Neuromuscular Block, Intubation Condition and Surgical Condition, sponsored by Seoul National University Hospital. Completed at 1 site in Korea, Republic of. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2016-04-18.

Sponsored by Seoul National University Hospital · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
84
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Study summary

This study aims to evaluate effects of magnesium sulfate on onset and duration of low dose rocuronium, intubation condition and surgical condition.

02

Conditions studied

  • Observation of Neuromuscular Block
  • Intubation Condition
  • Surgical Condition

Browse trials for

Keywords

  • magnesium sulfate, rocuronium
03

In context

Disease

1,327 studies on the registry are indexed under Disease; 596 are open to participants now.

This study's planned enrollment of 84 is close to the median of 80 across 732 interventional studies indexed under Disease.

Browse Disease studies →

Lead sponsor

Seoul National University Hospital is the lead sponsor of 1,860 studies on the registry; 275 are open to participants now.

Of its 12 completed or terminated interventional studies of FDA-regulated products, 2 (17%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • 18-75 yr American Society of Anesthesiologists physical status 1 or 2, BMI of 20-24.9 kg/m2 scheduled for elective laryngeal microsurgery

Exclusion criteria

Exclusion Criteria:

  • severe respiratory or cardiac disease hepatic or renal function impairment neuromuscular disease on medications affecting neuromuscular function with known allergy to the drugs
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
84 participants (estimated)

Study arms

  • Active comparator
    standard dose rocuronium group

    pretreatment of saline 100ml and rocuronium 0.6 mg/kg

    Drug: saline

  • Active comparator
    low dose rocuronium group

    pretreatment of saline 100ml and rocuronium 0.45 mg/kg

    Drug: saline

  • Active comparator
    low dose rocuronium plus magnesium group

    pretreatment of magnesium sulfate 30 mg/kg and rocuronium 0.45 mg/kg

    Drug: magnesium sulfate 30 mg/kg

Interventions

  • Drugmagnesium sulfate 30 mg/kg

    Patients in each group received the magnesium sulfate 30 mg/kg for 2 min in 0.9% normal saline (total volume 100 ml) intravenously for 5 min before induction of anesthesia

  • Drugsaline

    Patients in each group received 0.9% normal saline (total volume 100 ml) alone intravenously for 5 min before induction of anesthesia

06

What researchers measure

Primary outcomes

  1. onset time of rocuronium

    from injection of rocuronium to T1 suppression more than 95% up to 10 minutes

    Time frame: from injection of rocuronium to T1 suppression more than 95% up to 10 minutes

Secondary outcomes

  1. maximal suppression time and duration of rocuronium

    Time frame: time from the injection of rocuronium to T1 maximal suppression time and reversal of T1 25% up to 1 hours

Other outcomes

  1. intubation condition

    We scored intubation condition on the basis of 4 items, laryngoscopy, vocal cord position, moving of limbs, and coughing.

    Time frame: intubation condition during induction of anesthesia up to 10 minutes

  2. surgical condition

    to score a surgical condition according to 7 point likers scale

    Time frame: intraoperative surgical condition

  3. postoperative sore throat

    Time frame: postoperative sore throat up to 4 hours

07

Study locations

1 site
  • Seoul National Univ. Bundang Hospita
    Seongnam-si, Gyeonggi-do 463-707, Korea, Republic of
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Apr 18, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02100293
Lead sponsor
Seoul National University Hospital
Responsible party
Sponsor
First posted
Mar 31, 2014
Start date
Oct 2013
Primary completion
Dec 2014
Completion
Dec 2014
Last update
Apr 18, 2016

Study contacts

Sang Hwan Do
principal investigator · Seoul National Univ. Bundang Hospital

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion